Bristol Myers Squibb (BMY) reported $12.27 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 0.6%. EPS of $1.46 for the same period compares to $2.07 a year ago.
The reported revenue represents a surprise of +7.67% over the Zacks Consensus Estimate of $11.4 billion. With the consensus EPS estimate being $1.07, the EPS surprise was +36.45%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Bristol Myers performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net sales- Cobenfy- Worldwide: $35 million versus $28.25 million estimated by five analysts on average.
- Net Sales- Opdivo- U.S.: $1.51 billion compared to the $1.38 billion average estimate based on four analysts. The reported number represents a change of +7.1% year over year.
- Net Sales- Pomalyst/Imnovid- U.S.: $584 million compared to the $627.82 million average estimate based on four analysts. The reported number represents a change of -18.4% year over year.
- Net Sales- Pomalyst/Imnovid- International: $124 million compared to the $95.34 million average estimate based on four analysts. The reported number represents a change of -49% year over year.
- Net Sales- Revlimid: $838 million compared to the $625.54 million average estimate based on five analysts. The reported number represents a change of -38.1% year over year.
- Net Sales- Opdivo: $2.56 billion versus $2.4 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +7.3% change.
- Net Sales- Abraxane: $105 million compared to the $102.66 million average estimate based on five analysts. The reported number represents a change of -54.6% year over year.
- Net Sales- Reblozyl: $568 million versus the five-analyst average estimate of $546.45 million. The reported number represents a year-over-year change of +33.7%.
- Net Sales- Zeposia: $150 million versus $129.3 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -0.7% change.
- Net Sales- Breyanzi: $344 million compared to the $299.75 million average estimate based on five analysts. The reported number represents a change of +124.8% year over year.
- Net Sales- Abecma: $87 million versus the five-analyst average estimate of $99.76 million. The reported number represents a year-over-year change of -8.4%.
- Net Sales- Opdualag: $284 million compared to the $276.44 million average estimate based on five analysts. The reported number represents a change of +20.9% year over year.
View all Key Company Metrics for Bristol Myers here>>>
Shares of Bristol Myers have returned -3.5% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol Myers Squibb Company (BMY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
